This site uses cookies.

Some of these cookies are essential, while others help us to improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy

Select preferencesReject optionalAccept all

Cookie preferences

This website uses cookies so that we can provide you with the best user experience possible. Our Cookie Notice is part of our Privacy Policy and explains in detail how and why we use cookies. To take full advantage of our website, we recommend that you click on “Accept All”. You can change these settings at any time via the button "Update Cookie Preferences" in our Cookie Notice.

Necessary cookies (required)

Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.

Analytical cookies

Analytical cookies help us to improve our website by collecting and reporting information on its usage.

Submit preferencesAccept all
Home: Maucher Jenkins

Intellectual Property

Intellectual
Property

Patents | Trade Marks | Designs

Home>  About IP & News> News & Commentary

News & Commentary

Author:

James Cross

Partner - Patents | Litigation

IP in the digital age: a tricky path ahead for pharma companies

Date: 20 September 2016

James Cross, Partner at Maucher Jenkins, has contributed to an article published by Life Sciences Intellectual Property Review concerning IP protection in the world of digital health and the need for pharmaceutical companies to adjust in the digital age.

 

You can read the full article from LSIPR by clicking here.

Next articlePrevious article
EmailTwitterLinkedInXingWeChat
LinkedInTwitterWeChat
Regulated by IPReg©2025 Maucher JenkinsWebsite by Storm12
Sitemap|Terms of Business|Legal Notices|Privacy|Bribery Act|Complaints|Jenkins IP Ltd 1987 Retirement Savings Scheme
DECNClose menu